CD8A and breast cancer: Interestingly, terminally exhausted CD8 TILs were not responsive to single anti-PD-1 treatment in vitro but could be reinvigorated through combined checkpoint blockade with anti-PD-1 and anti-TIGIT, another checkpoint molecule that was found to be co-expressed on CD8 TILs from BC.